Stockreport

MiNK Therapeutics Announces Collaboration with C-Further to Advance PRAME-Targeted iNKT Cell Therapy for Pediatric Cancers

MiNK Therapeutics, Inc.  (INKT) 
PDF Selected as a C-Further program with up to ~$1.1 million in non-dilutive, aggregate payments to advance IND-enabling development, with potential for meaningful double-di [Read more]